165 Impact of Lemborexant on Insomnia Disease Severity and Fatigue: Results from the 6-Month Placebo-Controlled Period of the Phase 3 SUNRISE-2 Study

• Published in: CNS spectrums Vol. 25; no. 2; pp. 305 - 306
• Main Authors: Moline, Margaret, Kärppä, Mikko, Yardley, Jane, Kumar, Dinesh, Pinner, Kate, Perdomo, Carlos, Filippov, Gleb, Atkins, Norman
• Format: Journal Article
• Language: English
• Published: United States Cambridge University Press 01.04.2020
• Subjects: Double-blind studies; Insomnia
• ISSN: 1092-8529; 2165-6509
• DOI: 10.1017/S1092852920000814

This study examined the effects of lemborexant (LEM) compared with placebo (PBO) on subject-reported insomnia disease severity, assessed by the Insomnia Severity Index (ISI), and fatigue, assessed by the Fatigue Severity Score (FSS), from the 6-month PBO-controlled period of SUNRISE-2. SUNRISE-2 (NC...